1-855-378-42281-855-378-4228
One of the out-patient rehab alternatives for people in Fithian who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed centers and doctors are certified to administer specific medications to opioid addicted clients, many of which are opioid-based also and are addictive. With low amounts the client does not experience being high and also doesn't have acute cravings and is not experiencing opioid withdrawal. Methadone is the first drug administered for this sole purpose, but there are alternative options currently to choose from.
Methadone is an opiate and is meant to be taken at an out-patient medical center licensed to dispense the med, that is taken on a daily basis in liquid or pill form. The cost of the med is around $150 per month. Buprenorphine is also an opioid-based drug, and is in pill form often taken every other day. But unlike Methadone that can only be dispensed in highly well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The price monthly of buprenorphine is about three hundred dollars monthly for the generic version of the medication. There is also a type of buprenorphine containing the drug naloxone, that is a med which reverses the effects of opioids. An individual consuming this formulation, AKA Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken daily, and costs about $450 /month. Naltrexone is another drug taken in opioid maintenance therapy, but unlike the other drugs mentioned here it's an opiate blocker and isn't an opiate. A person has the choice to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents an individual from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 /month.
For All Alcohol and Drug Rehabilitation Facilities In Fithian, Click Here.
